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The renin-angiotensin system (RAS) plays a regulatory role in cardiovascular function and a pathogenic role in the development of hypertension and associated cardiovascular disorders. In addition to the classic endocrine system, local RASs are present in various tissues throughout the body, interacting with each other and the endocrine RAS.

Angiotensinogen (AGT) is the unique known precursor of angiotensin (Ang) peptides, which is transformed by renin to generate the decapeptide Ang I. Ang I is then converted by angiotensin-converting enzyme (ACE) into the octapeptide Ang II. Ang II is one of the major players in the RAS, acting on various receptors such as Ang II type 1 (AT1R) and type 2 receptors (AT2R). By binding to AT1R, Ang II promotes vasoconstriction, cell proliferation, and fibrosis, whereas when binding to AT2R it promotes the inhibition of cell growth. Most of the effects of Ang II have been shown to be mediated by AT1R. Increased activity of the RAS is associated with various cardiovascular diseases such as hypertension and heart failure. Classical treatment of RAS-associated diseases focuses on the blockade of Ang II formation or effects through the use of ACE inhibitors and AT1R blockers \[[@CR1]\].

ACE2 is a new component of the RAS that was discovered in 2000 \[[@CR2], [@CR3]\]. It is the first known human homologue of ACE but differs from ACE in substrate specificity. Although ACE2 was first shown to cleave Ang I to Ang (1-9) \[[@CR3]\], which can be converted by ACE into the heptapeptide Ang-(1-7), another study showed that ACE2 hydrolysis of Ang II into Ang-(1-7) has a much higher efficiency (∼400-fold) than that for Ang I to Ang (1-9) \[[@CR4]\].

It has been established that Ang-(1-7) acting on the Mas receptor mediates vasodilation, antiproliferation, and apoptosis \[[@CR5]\], therefore opposing the effects of Ang II. Using genetic and pharmacologic approaches, such as gene knockout, knockdown, gene transfer, activators and inhibitors, ACE2 has been shown to have protective effects in various tissues and to prevent overactive RAS-associated diseases, including hypertension \[[@CR6]\]. Thus, the new arm of the RAS, the ACE2-Ang-(1-7)-Mas axis, has been shown to be effective at counter-regulating the effects of the classic ACE-Ang II-AT1R axis.

Brain RAS contains the same elements as the other tissue RAS. Besides Ang II and AT1R, all the other components of RAS such as AGT, renin, AT2R, ACE, Ang IV, Ang-(1-7), Mas, and new elements such as prorenin/renin receptor and Ang-(1-12), have been identified in the central nervous system \[[@CR7], [@CR8]\]. However, the distribution of the new element ACE2 in the brain was at first controversial because original reports failed to identify the carboxypeptidase in this tissue \[[@CR2], [@CR3]\]. A few years later, ACE2 mRNA and protein were found in the brain by our group and others \[[@CR9]--[@CR11]\]. Using a selective antibody, we reported that ACE2 is widespread throughout the mouse brain, present in nuclei involved in the central regulation of cardiovascular function such as the subfornical organ, paraventricular nucleus (PVN), nucleus of the tractus solitarius (NTS), and rostral ventrolateral medulla (RVLM), as well as in noncardiovascular areas such as the motor cortex and raphe (Fig. [1](#Fig1){ref-type="fig"}). Shortly after our observation, Lin et al. \[[@CR12]•\] confirmed the presence of ACE2 mRNA and protein in the mouse brainstem and reported the interaction between ACE2 and AT1R in this region. These data suggest that ACE2 is actively involved in the brain RAS function. Fig. 1Angiotensin-converting enzyme 2 (ACE2) expression in the mouse brain. ACE2 is widely expressed throughout the mouse brain, including in key brain regions involved in the regulation of blood pressure and body fluid homeostasis. This shows examples of ACE2 expression (*red*) in the subfornical organ (SFO), the neurons of the paraventricular nucleus (PVN), the nucleus of tractus solitarii (NTS), the dorsal motor nucleus of the vagus (DMNX), and the rostral ventrolateral medulla (RVLM). *Green*: MAP2 (neuronal marker); *blue*: DAPI (nuclei marker). *CVLM*---caudal ventrolateral medulla; *IML*---intermediolateral cell column; *NA*---nucleus ambiguus

In the central nervous system, Ang II acting on AT1R results in cardiac baroreflex desensitization and resetting, increased sympathetic outflow, vasopressin release, and stimulation of the water intake, leading to the increase in blood pressure \[[@CR13]\]. It has been shown that upregulated AGT, ACE, Ang II, and AT1R in the brain are involved in the development and maintenance of hypertension and heart failure \[[@CR7], [@CR14]\]. Similar to the observations in the periphery, Ang-(1-7) shows opposite properties to Ang II in the central nervous system, serving as an important neuromodulator in the central control of cardiovascular function. It has been well demonstrated that central Ang-(1-7) increases cardiac baroreflex sensitivity \[[@CR15], [@CR16]\], reduces norepinephrine release \[[@CR17]\] and decreases blood pressure \[[@CR18], [@CR19]\] in hypertensive rats. The depressor effects of Ang-(1-7) in the brain have also been shown to be mediated by increase in bradykinin levels \[[@CR20]\], potentiating the hypotensive effects of bradykinin \[[@CR21]\] and stimulating nitric oxide (NO) release \[[@CR22]\]. ACE2 provides an important route for the metabolism of Ang II and, as the principal forming enzyme for Ang-(1-7), shifts the balance between the two biological active peptides.

However, compared with the well-established central effects of Ang II and Ang-(1-7), there are very few studies supporting the central nervous system effects of ACE2. Most of the studies have focused on the role of ACE2 in the kidney, heart, lung, liver, and other peripheral tissues, as evidenced by the numerous reviews on ACE2 \[[@CR23]--[@CR27]\]. However, with the discovery of ACE2 in the brain, the role of ACE2 in the central nervous system gained increasing attention from the scientific community. In recent years, growing evidence has demonstrated the important role of ACE2 in the central nervous system, such as in blood pressure control \[[@CR28], [@CR29]•, [@CR30], [@CR31]••\].We previously reviewed the central effects of ACE2 and discussed the potential for this carboxypeptidase as a new target in the treatment of cardiovascular diseases \[[@CR6]\]. In this report, we updated this information by reviewing the recent discoveries of the past 1 year to 2 years, specifically focusing on the role of ACE2 in the brain RAS and its effects on central regulation of cardiovascular function.

ACE2 Interacts with Other Components of the Brain RAS {#Sec2}
=====================================================

Over the past 1 year to 2 years, more studies from various groups have demonstrated that ACE2 can affect or be affected by other components of the RAS in the central nervous system. An in vitro study from Xiao et al. \[[@CR32]\] showed that overexpression of ACE2 in neurons attenuates the Ang II--induced upregulation of AT1R, which could result from inhibition of the well-known feed-forward effect of Ang II on its receptor. In vivo, our group showed that overexpression of ACE2 in the mouse brain not only reduces AT1R expression as previously suggested \[[@CR30]\] but also increases Mas and AT2R \[[@CR33]••\], whereas blockade of AT1R increases brain ACE2 activity in hypertensive mice \[[@CR31]••\]. Using a gene-silencing approach, Lin et al. \[[@CR12]•\] reported that downregulation of AT1R mRNA is associated with downregulation of ACE2 mRNA in the mouse brainstem. In addition, downregulated ACE2 is accompanied by upregulation of ACE levels in the brain of a heart failure animal model \[[@CR34]\] and in multiple sclerosis patients \[[@CR35]\], indicating a special link between ACE2 and ACE in the brain. These data confirmed and extend previous findings that ACE2 interacts with other RAS components in the brain and strengthens the concept that ACE2 is a significant player in the brain RAS.

ACE2 and Cardiovascular Diseases {#Sec3}
================================

Alteration of ACE2 expression or activity in the brain has been found in pathologic conditions related to cardiovascular diseases. Kawajiri et al. \[[@CR35]\] reported decreased ACE2 and increased ACE concentration in cerebrospinal fluid from patients with multiple sclerosis compared to those with non-neurologic diseases. Similarly, downregulated ACE2 and upregulated ACE protein and mRNA expression were observed in various brain nuclei (including PVN, NTS, and RVLM ) from pacing-induced chronic heart failure (CHF) rabbits with increased sympathetic nerve activity \[[@CR34]\]. These data suggest that the alteration of ACE/ACE2 in the brain is involved in the development of cardiovascular diseases. Moreover, we recently showed decreased ACE2 activity in the brain of a chronically hypertensive mouse model with increased Ang II level \[[@CR31]••\]. These observations support the critical role of ACE2 in the central nervous system in the maintenance of normal cardiovascular function.

Because decreased ACE2 in the central nervous system is associated with multiple cardiovascular diseases, compensation by ACE2, as a result of increasing or activating this enzyme, in the brain could provide beneficial effects on these diseases. Several studies showed the effects of ACE2 on prevention or attenuation of hypertension. Using adenovirus coding for ACE2, Sriramula et al. \[[@CR36]\] showed that PVN-targeted ACE2 overexpression attenuates the Ang II--induced pressor response in rats. Using a new transgenic mouse model (syn-hACE2) with neuron-targeted ACE2 overexpression, we found that the development of Ang II--induced neurogenic hypertension was blunted \[[@CR33]••\]. In additional experiments, the syn-hACE2 mice were bred with chronically hypertensive transgenic mice expressing both human renin and AGT genes \[[@CR37]\], to generate a triple-transgenic model (SARA) with elevated Ang II throughout the body and overexpression of human ACE2 selectively in the brain. Following chronic measurement of blood pressure in SARA mice, we observed that central overexpression of ACE2 significantly decreases baseline blood pressure in these chronically hypertensive mice \[[@CR31]••\]. However, the blood pressure was not normalized due to the chronic and widespread expression of Ang II in the periphery. Nevertheless, our observations are consistent with previous reports from Yamazato et al. \[[@CR28]\] and our group \[[@CR30]\] showing the antihypertensive effects of ACE2 in specific brain nuclei, such as RVLM and subfornical organ. In addition to these gene transfer approaches, Cangussu et al. \[[@CR38]\] showed that increases in ACE2 and Mas mRNA expression in the hypothalamus following exercise training in 2K1C rats are associated with a reduction of the increased systolic arterial pressure in these animals, although ACE2 levels were not altered in these hypertensive rats before exercise training compared with sham controls. Besides the role of ACE2 in the regulation of blood pressure, Lima et al. \[[@CR39]\] showed that central activation of ACE2 by intracerebroventricular injection of XNT, an activator of endogenous ACE2, attenuates air jet stress-induced tachycardia in rats, suggesting the beneficial effects of ACE2 on cardiac function.

ACE2 Modulates Baroreflex and Autonomic Functions {#Sec4}
=================================================

Several studies have focused on the mechanisms involved in ACE2 regulation of blood pressure and other cardiovascular functions. Baroreflex sensitivity and autonomic function are important central mechanisms modulating blood pressure and other cardiovascular functions. It has been shown that inhibition of ACE2 activity in the NTS, by injecting a specific inhibitor in this region, reduces the sensitivity of the baroreceptor reflex control of heart rate to increases in arterial pressure \[[@CR29]•\]. Similarly, we previously showed that *ACE2* gene deletion on a C57bl/6 background mouse resulted in impairment of the spontaneous baroreflex sensitivity (SBRS), increased sympathetic tone, and decreased parasympathetic tone \[[@CR40], [@CR41]\]. Moreover, exercise training--induced increase in endogenous ACE2 in the brain of CHF rabbits was associated with an attenuation of sympathetic nerve activity in these animals \[[@CR34]\]. Also, overexpressing ACE2 in the PVN, by virus-mediated gene transfer, improves renal sympathetic nerve activity in coronary ligation-induced CHF rats \[[@CR42]\]. Global overexpression of ACE2 in the brain also restored the impaired SBRS, normalized the increased sympathetic tone, and decreased parasympathetic tone in transgenic hypertensive mice, contributing to the attenuation of hypertension in these animals \[[@CR31]••\]. In low-dose Ang II infusion, a model of neurogenic hypertension, although ACE2 overexpression in the brain did not alter the increased sympathetic tone, it significantly prevented the decrease in both SBRS and parasympathetic tone and attenuated the development of hypertension \[[@CR33]••\]. Similar observations were made by Gao et al. \[[@CR43]\] showing that global overexpression of exogenous ACE2 in the brain prevents impairment of baroreflex sensitivity and sympathoexcitation in the CHF state.

These data suggest that ACE2 is involved in baroreflex control mechanisms and is able to modulate sympathetic and parasympathetic tones, thus participating in long-term and short-term regulation of blood pressure as well as cardiac function. The modulation of baroreflex and autonomic function by ACE2 could be independent of Ang II level, since measurement of Ang II in the brain and plasma showed no change in adult ACE2-deficient mice in which baroreflex and autonomic function were impaired \[[@CR41]\]. However, the ACE2-mediated changes in baroreflex and autonomic function could also be resulting from, at least partially, metabolism of Ang II in the brain in some conditions, as decreased water intake following ACE2 overexpression in the brain was observed in both of the two hypertensive models mentioned above \[[@CR31]••, [@CR33]••\]. Moreover, similar to the effects of Ang-(1-7) \[[@CR15], [@CR16]\], intracerebroventricular infusion of a novel ACE2 product peptide, Ala1-Ang-(1-7), increases baroreflex sensitivity for reflex bradycardia \[[@CR44]\], suggesting the modulation of ACE2 on baroreflex function could also be triggered by its products.

ACE2 Mechanisms Involve NO Synthase and Reactive Oxygen Species Signaling {#Sec5}
=========================================================================

In the central nervous system, it has been shown that NO reduces, whereas oxidative stress increases, sympathetic activity \[[@CR45]--[@CR47]\]. Overexpressing ACE2 in the PVN normalized the decreased neuronal nitric oxide synthase (NOS) protein levels in this region in CHF rats and was accompanied with improved sympathetic nerve activity, suggesting the inhibitory effects of ACE2 on sympathoexcitation involve an NO mechanism \[[@CR42]\]. Similarly, Gao et al. \[[@CR43]\] showed that overexpression of ACE2 in the brain prevented the downregulation of NOS expression in the CHF mice, contributing to the improvement of baroreflex sensitivity and the reduction of sympathoexcitation. This is confirmed by our observation showing that overexpression of ACE2 in the brain upregulated NOS expression and increased NO levels in the cerebrospinal fluid \[[@CR33]••\]. In addition, ACE2 overexpression in the brain prevented the Ang II--mediated decrease in NOS expression in regions modulating blood pressure regulation \[[@CR33]••\]. Furthermore, we observed that *ACE2* gene deletion leads to increased superoxide levels in various brain nuclei of aged mice \[[@CR48]\], supporting the antioxidant capacity of ACE2 in the brain. These data indicate that the protective effects of ACE2 could be linked to an increased NO availability and decreased oxidative stress in the brain.

Conclusions and Perspectives {#Sec6}
============================

Clear progress has been made in our understanding of the role of ACE2 in the brain. The many beneficial effects of this carboxypeptidase on the central regulation of cardiovascular function could be independent or at least partially result from the modification of angiotensin peptides. The potential therapeutic implications of ACE2 suggest that it could be used to treat hypertension, heart failure, and other cardiovascular diseases. Increasing brain ACE2 by stimulating endogenous ACE2 activity and/or expression, or administration of exogenous ACE2 may provide beneficial effects in some pathologic conditions and this could be a new strategy for future development of novel therapeutic agents. Further understanding of its role in the central nervous system is needed because it would lead to the exploration of novel therapies for neurogenic hypertension and other cardiovascular as well as neurologic diseases.
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